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Abstract Transforming growth factor-L (TGF-L) is a potent
anti-inflammatory cytokine. Although this cytokine inhibits
lipopolysaccharide (LPS)-mediated septic shock, the molecular
mechanism of TGF-L is not well known. Since recent studies
showed that c-Jun N-terminal kinase (JNK), one of the mitogen-
activated protein kinases, plays an important role in LPS
signalling, we focused here on the inhibitory action of TGF-L1 on
LPS-stimulated JNK activity in mouse macrophages. TGF-L1
inhibited LPS-stimulation of phosphorylated JNK1 and JNK2
and consequently of JNK activity in the cells. This JNK activity
resulted in a decreased level of phosphorylated c-Jun protein.
Using Western blotting, we also observed TGF-L1 inhibition of
newly synthesized c-Jun protein in LPS-stimulated cells. These
results demonstrate that TGF-L1 inhibits LPS-stimulated JNK
activity in mouse macrophages. Also, our present study suggests
a possible inhibitory mechanism of TGF-L in signalling of LPS-
induced inflammatory responses.
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1. Introduction
Transforming growth factor-L (TGF-L) plays important
roles in growth and development, in£ammation and repair
and host immunity [1^3]. Many studies [4^8] have demon-
strated inhibitory actions of this cytokine in immunological
and in£ammatory responses. In fact, various interesting stud-
ies [9^12] have shown that the progressive in£ammation found
in TGF-L1-de¢cient mice is associated with several manifes-
tations of autoimmunity, including circulating antibodies to
nuclear antigens and immune complex deposition. These ¢nd-
ings strongly demonstrate that TGF-L1 is a potent anti-in-
£ammatory cytokine. However, the molecular mechanism of
anti-in£ammatory action of TGF-L1 has still not been inves-
tigated.
LPS stimulates in£ammatory responses via production of
cytokines such as interleukin (IL)-1, IL-6 and TNF-K by mac-
rophages and neutrophils that express predominantly the
membrane receptor CD14 [13^20]. Therefore, it is very impor-
tant to demonstrate the intracellular mechanism of signal
transduction in LPS-stimulated in£ammatory responses. Re-
cently, several investigations [21^25] have suggested that espe-
cially c-Jun N-terminal kinase (JNK), one of the mitogen-
activated protein (MAP) kinases, plays a predominant role
in lipopolysaccharide (LPS) signalling.
In light of these facts and to demonstrate the molecular
mechanism of the anti-in£ammatory action of TGF-L1, it is
of interest to investigate whether TGF-L1 is able to inhibit
LPS-stimulated JNK activity in mouse macrophages. Our
present study demonstrates TGF-L1 inhibition of LPS-stimu-
lated JNK activity in mouse macrophages.
2. Materials and methods
2.1. Reagents
TGF-L1 was puri¢ed from human platelets to homogeneity
(s 98%, determined by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and HPLC analyses: PEPROTECH,
London, UK). RPMI 1640 was obtained from Nissui Pharmaceutical
(Tokyo, Japan) and fetal calf serum from Hyclone (Logan, UT,
USA). Escherichia coli 0111 B4-derived LPS was from Sigma Chem-
ical (St. Louis, MO, USA). [Q-32P]ATP was purchased from Amer-
sham Pharmacia Biotech (Tokyo, Japan). The phospho-speci¢c
SAPK/JNK antibody (Thr-183/Tyr-185), control anti-SAPK/JNK
antibody, phospho-speci¢c c-Jun(Ser-63) II antibody, phospho-specif-
ic c-Jun(Ser-73) antibody and control c-Jun antibody were all rabbit
polyclonal antibodies purchased from New England Biolabs (Beverly,
MA, USA).
2.2. Preparation of mouse peritoneal macrophages
BALB/c mice, 7 weeks of age, were injected intraperitoneally with
3 ml of thioglycollate medium (Difco, Detroit, MI, USA). Peritoneal
macrophages were prepared from the mouse peritoneal exudate cells
as described earlier [26]. The prepared macrophages were treated for
selected times with test samples.
2.3. Western blot analysis
Macrophage monolayers in 9 cm diameter dishes (5U106 peritoneal
exudate cells) were incubated in the presence or absence of test sam-
ples at various concentrations. Thereafter, the cells were solubilized
with lysis bu¡er (20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM
EGTA, 1 mM EDTA, 1% (v/v) Triton X-100, 2.5 mM sodium pyro-
phosphate, 1 mM Na3VO4, 1 mM L-glycerolphosphate, 1 Wg/ml leu-
peptin, 1 mM PMSF). The samples (20 Wg protein) were electropho-
resed on 10% polyacrylamide gels by SDS-PAGE using a Tris-glycine
bu¡er system (0.025 M Tris, 0.192 M glycine, 0.1% SDS). The protein
was transferred to a polyvinylidene di£uoride membrane (Millipore,
Bedford, MA, USA) by making use of the semidry transblot system
(ATTO, Tokyo, Japan). Blots were blocked with 5% skin milk in Tris-
bu¡ered saline including 0.1% Tween-20 (TBS-T) for 1 h at room
temperature and washed with TBS-T. Then, the membrane was incu-
bated with the primary antibody diluted 1:1000 in 5% bovine albumin
in TBS-T, overnight at 4‡C. Protein was detected with a Phototope-
HRP Western blot detection kit (New England Biolabs). The blots
were exposed to X-omat ¢lm (Eastman Kodak, Rochester, NY, USA)
2.4. JNK activity assay
The activity of JNK was measured using the SAPK/JNK assay kit
(New England Biolabs) according to the instructions from the manu-
facturer. Brie£y, macrophage monolayers in 9 cm diameter dishes
(5U106 peritoneal exudate cells) were incubated in the presence or
absence of test samples at various concentrations. Thereafter, the cells
were solubilized with lysis bu¡er (20 mM Tris-HCl (pH 7.4), 150 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton X-100, 2.5 mM
sodium pyrophosphate, 1 mM Na3VO4, 1 mM L-glycerolphosphate,
1 Wg/ml leupeptin, 1 mM PMSF). Then, the cell lysates were incubated
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with GST-c-Jun coupled to GSH-Sepharose beads, overnight at 4‡C,
to precipitate JNK. After the beads were washed, the solid-phase
kinase reaction was carried out at 30‡C for 30 min in kinase bu¡er
(25 mM Tris-HCl (pH 7.5, 150 mM NaCl, 2 mM dithiothreitol, 0.1
mM Na3VO4, 5 mM L-glycerolphosphate, 10 mM MgCl2, 100 mM
ATP). The reaction was terminated by adding sample bu¡er (62.5
mM Tris-HCl (pH 6.8), 2% (w/v) SDS, 10% glycerol, 50 mM DTT,
0.1% (w/v) bromophenol blue). Phosphorylation of GST-c-Jun on
Ser-63 was analyzed after SDS-PAGE and immunoblotting with
phospho-speci¢c c-Jun(Ser-63) antibody.
3. Results
3.1. TGF-L1 inhibits LPS stimulation of phosphorylation of
JNK1 and JNK2 in mouse macrophages
Since JNK is one of the major regulatory molecules in
signal transducing mechanisms in macrophages stimulated
by LPS, ¢rstly, we investigated whether TGF-L1 modulates
phosphorylation of Thr-183 and Tyr-185 of JNK in macro-
phages stimulated with LPS. The cells were treated or not
with TGF-L1 at various times prior to LPS addition at 100
ng/ml and then, two apparent bands, p46 (JNK1) and p54
(JNK2), were analyzed by an immunoblot assay with phos-
pho-speci¢c JNK antibody. As shown in Fig. 1A and B,
although LPS stimulated in a treatment time- and dose-de-
pendent manner the phosphorylation of the two JNKs in the
cells, TGF-L1 inhibited this stimulation dramatically. The
TGF-L1 inhibition of JNK1 and JNK2 was observed to be
signi¢cant after at least 3 h of pretreatment and was pretreat-
ment time-dependent (Fig. 1C). However, stimulation of non-
phosphorylated JNK protein production was not observed in
LPS-treated cells and TGF-L1 did not reduce the level of non-
phosphorylated JNK protein (Fig. 1D). These results show
that TGF-L1 inhibited LPS-induced phosphorylation of
JNK1 and JNK2 in mouse macrophages.
3.2. TGF-L1 inhibits LPS-stimulated JNK activity in mouse
macrophages
The TGF-L1 inhibition of LPS-stimulated phosphorylation
of JNKs suggested that TGF-L1 may be able to inhibit the
toxin-stimulated JNK activity in mouse macrophages. There-
fore, we examined TGF-L1 inhibition of LPS-stimulated JNK
activity in LPS-stimulated cells. The cells were treated or not
for 24 h with TGF-L1 prior to LPS addition and then, JNK
activity in the cell lysates was analyzed at 1 h after the addi-
tion of LPS. Fig. 2A shows that LPS stimulation of JNK
activity in the cells was dose-dependent. Importantly, TGF-
L1 clearly inhibited LPS-stimulated JNK activity in the cells
(Fig. 2B).
3.3. TGF-L1 inhibits LPS stimulation of c-Jun phosphorylation
in mouse macrophages
Since TGF-L1 inhibition of LPS-stimulated JNK activity in
macrophages suggested that this cytokine may inhibit LPS-
induced phosphorylation of c-Jun, we examined this point
by conducting an immunoblot assay with two antibodies
Fig. 1. TGF-L1 inhibits LPS-stimulated phosphorylation of JNK1 and JNK2 in mouse peritoneal macrophages. (A) The cells from BALB/c
mice were treated or not for the selected periods with LPS at 100 ng/ml. Thereafter, phosphorylation of JNK1 and JNK2 in equal amounts of
cell lysates was analyzed after SDS-PAGE and immunoblotting with antibody against phosphorylated JNK1 and JNK2. (B) The cells from
BALB/c mice were treated or not for 1 h with LPS at various doses. Thereafter, phosphorylation of JNK1 and JNK2 was detected as described
in ‘A’. (C) The cells from BALB/c mice were pretreated or not for the selected times with TGF-L1 at 1 ng/ml and then treated or not for 1 h
with LPS at 100 ng/ml. Thereafter, phosphorylation of JNK1 and JNK2 was detected as described in ‘A’. (D) The experimental conditions
were the same as in ‘C’. Then, JNK in equal amounts of cell lysates was analyzed after SDS-PAGE and immunoblotting with anti-JNK anti-
body. An identical experiment independently performed gave similar results.
Fig. 2. TGF-L1 inhibits LPS-stimulated JNK activity in mouse peri-
toneal macrophages. (A) The cells from BALB/c mice were treated
or not for 1 h with LPS at various doses. Thereafter, equal amounts
of the cell lysates were incubated with GST-c-Jun coupled to GSH-
Sepharose beads to precipitate JNK. After the beads were washed,
the solid phase kinase reaction was carried out at 30‡C for 30 min.
Phosphorylation of GST-c-Jun on Ser-63 was analyzed after SDS-
PAGE and immunoblotting with phospho-speci¢c c-Jun (Ser-63)
antibody. (B) The cells were pretreated or not for 24 h with TGF-
L1 at the selected doses and then treated or not for 1 h with LPS
at 100 ng/ml. The JNK activity was determined as described in ‘A’.
An identical experiment independently performed gave similar re-
sults.
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that recognize c-Jun phosphorylated at Ser-63 and Ser-73,
respectively. The cells were treated or not for 24 h with
TGF-L1 at 1 ng/ml and then treated or not for various times
with LPS at 100 ng/ml. Then, phosphorylation of c-Jun on
Ser-63 and Ser-73 in cell lysates was analyzed after SDS-
PAGE and immunoblotting with each antibody. As shown
in Fig. 3, LPS stimulation of phosphorylation of c-Jun on
Ser-63 and Ser-73 in the cells was observed to be marked after
at least 15 min of LPS treatment. Also, as expected, TGF-L1
strongly inhibited LPS-stimulated phosphorylation of the on-
cogene product.
3.4. TGF-L1 inhibits LPS-stimulated synthesis of c-Jun protein
in mouse macrophages
Finally, we addressed by a Western blot assay whether
TGF-L1 is able to inhibit newly synthesized c-Jun protein in
LPS-treated macrophages. As shown in Fig. 4A, this cytokine
inhibited LPS-stimulated production of c-Jun protein by the
cells in a dose-dependent manner and the inhibitory e¡ect was
observed as early as 5 min after the initiation of the LPS
stimulation (Fig. 4B). These results clearly showed that
TGF-L1 is able to inhibit LPS-stimulated synthesis of c-Jun
protein in the macrophages.
4. Discussion
LPS activates three separate MAP kinases, i.e. JNK, extra-
cellular signal-regulated kinase and p38, in a macrophage cell
line (34-41). Especially, it is well known that JNK regulates
the transcription of many genes by activating AP-1 with a
relative high speci¢city. In fact, a recent study [27] showed
the direct involvement of JNK in the biosynthesis of TNF-
K, a major mediator of septic shock, in macrophages. There-
fore, we focused our present study on the regulatory action of
TGF-L1 on LPS-stimulated JNK activity in murine macro-
phages. We showed here that TGF-L1 acts as a potent inhib-
itor of LPS-stimulated activity of JNK in the macrophages.
Pretreatment of mouse macrophages with TGF-L1 inhibited
LPS-stimulated phosphorylation of JNK1 and JNK2 and also
that of c-Jun on Ser-63 and Ser-73 stimulated in the cells. In
addition, we showed that TGF-L1 blocked LPS-stimulated
JNK activity in the cells. In this regard, a recent study [27]
demonstrated that glucocorticoid, an another potent inhibitor
of in£ammation, also inhibits JNK activity in a LPS-stimu-
lated RAW macrophage cell line. However, the mechanism of
this inhibition is unknown. Also, although the inhibitory
mechanism of TGF-L1 with respect to JNK activity has
not yet been demonstrated, two possible inhibitory mecha-
nisms may be postulated: (1) TGF-L1 might inhibit JNK
by inducing phosphatase activity against TGF-L-activated
kinase (TAK1), a strong activator of JNK, or (2) the
TAK1CMKK4/SEK1CJNK kinase cascade is consumed
by TGF-L1 pretreatment and consequently, LPS is unable
to use JNK that is required in its signalling. In this regard,
several investigators have shown that TGF-L actually initiates
a signalling cascade leading to SAPK/JNK activation [28,29].
Therefore, in further studies, it is very important to elucidate
the mode of action of upstream compounds of JNK induced
by TGF-L1. In this study, although we focused on the inhib-
itory action of TGF-L1 in LPS-induced JNK, it also remains
of interest to explore this cytokine action toward other MAP
kinases that are activated in the LPS response.
Inducible NOS is a potent mediator of LPS-induced septic
shock. However, since TNF-K is a strong stimulator of iNOS
expression in several kinds of cells, we considered that it is
very important to examine the inhibitory action of TGF-L1
against LPS-stimulated expression of TNF-K in septic shock
in mice. Our preliminary study shows that TGF-L1 is able to
inhibit LPS-stimulated expression of TNF-K in mouse macro-
phages and that the TGF-L1 inhibitory e¡ect was also ob-
served in the lungs, kidneys and spleen of LPS-injected mice
(unpublished data). However, at present, we do not know
whether this inhibitory action in vivo is dependent on down-
regulation of JNK activity as observed in vitro.
In conclusion, the results of our present study have allowed
us to propose a possible molecular mechanism for the anti-
in£ammatory action of TGF-L1 in Gram-negative bacterial
infections.
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